EDN2 and chronic kidney disease: In our cohort, ET-2 concentrations were significantly higher in patients with advanced CKD and in subgroups characterized by elevated inflammatory markers (hsCRP and IL-6), whereas ET-1 and ET-3 did not show comparable group-wise differences.